

Centre for Human Drug Research to Sponsor the 14th annual Pain Therapeutics Conference

LONDON, UNITED KINGDOM, April 17, 2014 /EINPresswire.com/ -- SMi Group are delighted to announce that the Centre for Human Drug Research (CHDR) will be sponsoring the 14th annual [Pain Therapeutics](#) Conference taking place on 19th and 20th May in Central London.

The Centre for Human Drug Research (CHDR) offers a range of pain models to assess pain perception in healthy subjects and patient populations. When used in combination, the tests of the 'PainCart' battery can be an important investigational tool for assessing analgesic effects in early phase clinical trials. The complete battery of tests provides important information to demonstrate proof of concept or mechanism of action of a newly developed analgesic.

In addition to this, attendees at Pain Therapeutics will be able to hear more on microneurography as a method for recording individual action potentials from nociceptors and



Pain Therapeutics 2014



Microneurography can record and quantify spontaneous nerve impulses directly from peripheral nociceptors in animals and humans."

Jordi Serra, Neuroscience Technologies

its value in drug development in neuropathic pain. A keynote presentation by Jordi Serra, CSO from Neuroscience Technologies Ltd will analyse analgesic efficacy in preclinical animal models and review proof-of-concept studies that allow critical testing of presumed mechanism of actions.

When asked about microneurography, Jordi Serra said:

"Quantification of spontaneous pain in animals is still problematic. Current animals models mostly use measures

of evoked pain, with low translational value. Microneurography can record and quantify spontaneous nerve impulses directly from peripheral nociceptors in animals and humans. It has excellent face and construct validity to test the efficacy of new compounds in stopping abnormal ongoing activity in peripheral nociceptors."

Other areas to be covered at the event include a discussion on new mechanisms - bench to bedside, enhancing the translation of animal data into pain patients, advances in opioids and neuropathic pain.

For further details on the full speaker line-up and for a conference brochure visit the conference at www.pain-therapeutics.co.uk

A snap shot of those attending Pain Therapeutics 2014 include: Abbott Laboratories, Anderson Cancer Center, Eli Lilly, G W Pharmaceuticals, Johnson And Johnson, MC Mutual, Merck & Co, Mundipharma, Nektar Therapeutics, OGBConsulting, Spinifex Pharmaceuticals, Stockholm Brain Institute, Technology & Medicine, The Medicines Company, University Of Sheffield, UCB, University of Oxford, VETOQUINOL plus many more

PAIN THERAPEUTICS

19TH 20TH MAY 2014, LONDON UK

Holiday Inn Kensington Forum, London UK

www.pain-therapeutics.co.uk

ABOUT SMI GROUP

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries.

We pride ourselves on having access to the worlds most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries. More information can be found at www.smi-online.co.uk

ABOUT CENTRE FOR DRUG AND HUMAN RESEARCH

Centre for Human Drug Research provides a full range of early stage clinical pharmacology services. CHDR specializes in early proof of pharmacology and in the complex process of drug development, we offer an efficient route towards proof of concept in patients. By conducting highly informative early-phase clinical studies, development risks can be minimized and costs can be reduced. Visit <http://www.chdr.nl>

Teri Arri

SMi Group Ltd

+44 (0)20 7827 6162

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/200565078>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.